- $59.31m
- $52.81m
- $2.03m
Brief: Durect Doses First Ex-U.S. Patient In Phase 2B Study Of Severe Alcohol-Associated Hepatitis Treatment
Brief: Durect Posts Quarterly Loss Per Share Of $0.04
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Brief: Durect Corp Files For Mixed Shelf Of Up To $250 Mln
Durect Corp Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Durect Q2 Revenue $2.3 Million
Durect Corp Expected To Post A Loss Of 4 Cents A Share: Earnings Preview
Brief: DURECT Corp Presents Additional Clinical Data From DUR-928 Phase 1b Trial In NASH
Brief: Durect Corp Says On May 28, Co, Oxford Finance Llc Entered Into Fifth Amendment Of $20.0 Million Loan And Security Agreement
Durect Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Durect Q1 Revenue $2.2 Million
Durect Corp Expected To Post A Loss Of 4 Cents A Share: Earnings Preview
Brief: DURECT Corp Announces Q4 2020 Financial Results
Brief: DURECT Corporation Announces Proposed Offering Of Common Stock
Durect Corp: Jumps after FDA approves non-opiod painkiller
Brief: DURECT Corp Announces U.S. FDA Approval Of POSIMIR For Post-Surgical Pain Reduction For Up To 72 Hours Following Arthroscopic Subacromial Decompression
Brief: Durect Corp Announces First Patient Dosed In Phase 2B Ahfirm Study Of Dur-928 In Severe Alcohol-Associated Hepatitis
Brief: Durect Corp says Board Approved Increase In Size Of Board, From Eight To Ten Members
Brief: Durect Corporation Appoints Two New Board Members